Return to search

RemeGen lands $100m

RemeGen, a Chinese biopharmaceutical company, has raised $100 million in financing.

RemeGen, a Chinese biopharmaceutical company, has raised $100 million in financing. Lilly Asia Ventures and Lake Bleu Capital led the round with participation from other backers that included Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital, Loyal Valley Capital and China Reform Conson Soochow Overseas Fund.

Source: Press Release